

NIH Consensus Statement

Volume 15, Number 6
November 17-19, 1997



Effective Medical Treatment of Opiate Addiction

NATIONAL INSTITUTES OF HEALTH
Office of the Director

About the NIH Consensus Development Program

NIH Consensus Development Conferences are convened to evaluate available scientific information and resolve safety and efficacy issues related to a biomedical technology. The resultant NIH Consensus Statements are intended to advance understanding of the technology or issue in question and to be useful to health professionals and the public.

NIH Consensus Statements are prepared by nonadvocate, non-Federal panels of experts, based on (1) presentations by investigators working in areas relevant to the consensus questions during a 2-day public session, (2) questions and statements from conference attendees during open discussion periods that are part of the public session, and (3) closed deliberations by the panel during the remainder of the second day and morning of the third. This statement is an independent report of the consensus panel and is not a policy statement of the NIH or the Federal Government.

Reference Information

For making bibliographic reference to this consensus statement, it is recommended that the following format be used, with or without source abbreviations, but without authorship attribution:

Effective Medical Treatment of Opiate Addiction. NIH Consensus Statement 1997 Nov 17-19; 15(6): 1-38.

Continuing Medical Education

This Continuing Medical Education activity was planned and produced in accordance with the Accreditation Council for Continuing Medical Education Essentials.

Publications Ordering Information

NIH Consensus Statements, NIH Technology Assessment Statements, and related materials are available by writing to the NIH Consensus Program Information Center, P.O. Box 2577, Kensington, MD 20891; by calling toll-free 1-888-NIH-CONSENSUS (888-644-2667); or by visiting the NIH Consensus Development Program home page on the World Wide Web at <http://consensus.nih.gov>.



NIH Consensus Statement

Volume 15, Number 6

November 17-19, 1997

Date of original release: November 19, 1997

Effective Medical Treatment of Opiate Addiction

This statement reflects the panel's assessment of medical knowledge available at the time the statement was written. Thus, it provides a "snapshot in time" of the state of knowledge on the conference topic. When reading the statement, keep in mind that new knowledge is inevitably accumulating through medical research.



National Institutes Of Health

Continuing Medical Education

NATIONAL INSTITUTES OF HEALTH

Office of the Director

Disclosure Statement

All of the panelists who participated in this conference and contributed to the writing of this consensus statement were identified as having no financial or scientific conflict of interest, and all signed conflict of interest forms attesting to this fact. Unlike the expert speakers who present scientific data at the conference, the individuals invited to participate on NIH consensus panels are selected specifically because they are not professionally identified with advocacy positions with respect to the conference topic or with research that could be used to answer any of the conference questions.

Abstract

Objective

The objective of this NIH Consensus Statement is to inform the biomedical research and clinical practice communities of the results of the NIH Consensus Development Conference on Effective Medical Treatment of Opiate Addiction. The statement provides state-of-the-art information regarding effective treatments for opiate addiction and presents the conclusions and recommendations of the consensus panel regarding these issues. In addition, the statement identifies those areas of study that deserve further investigation. Upon completion of this educational activity, the reader should possess a clear working clinical knowledge of the state of the art regarding this topic. The target audience of physicians for this statement includes, but is not limited to, psychiatrists, family practitioners, psychologists, and behavioral medicine specialists.

Participants

A non-Federal, nonadvocate, 12-member panel representing the fields of psychology, psychiatry, behavioral medicine, family medicine, drug abuse, epidemiology, and the public. In addition, 25 experts from these same fields presented data to the panel and a conference audience of 600.

Evidence

The literature was searched through Medline and an extensive bibliography of references was provided to the panel and the conference audience. Experts prepared abstracts with relevant citations from the literature. Scientific evidence was given precedence over clinical anecdotal experience.

Consensus Process

The panel, answering predefined questions, developed their conclusions based on the scientific evidence presented in open forum and the scientific literature. The panel composed a draft statement that was read in its entirety and circulated to the experts and the audience for comment. Thereafter, the panel resolved conflicting recommendations and released a revised statement at the end of the conference. The panel finalized the revisions within a few weeks after the conference. The draft statement was made available on the World Wide Web immediately following its release at the conference and was updated with the panel's final revisions.

Conclusions

Opiate dependence is a brain-related medical disorder that can be effectively treated with significant benefits for the patient and society, and society must make a commitment to offer effective treatment for opiate dependence to all who need it. All opiate-dependent persons under legal supervision should have access to methadone maintenance therapy, and the U.S. Office of National Drug Control Policy and the U.S. Department of Justice should take the necessary steps to implement this recommendation. There is a need for improved training for physicians and other health care professionals and in medical schools in the diagnosis and treatment of opiate dependence. The unnecessary regulations of methadone maintenance therapy and other long-acting opiate agonist treatment programs should be reduced, and coverage for these programs should be a required benefit in public and private insurance programs.

Introduction

In the United States before 1914, it was relatively common for private physicians to treat opiate-dependent patients in their practices by prescribing narcotic medications. While the passage of the Harrison Act did not prohibit the prescribing of a narcotic by a physician to treat an addicted patient, this practice was viewed as problematic by Treasury officials charged with enforcing the law. Physicians who continued to prescribe were indicted and prosecuted. Because of withdrawal of treatment by physicians, various local governments and communities established formal morphine clinics for treating opiate addiction. These clinics were eventually closed when the AMA, in 1920, stated that there was unanimity that prescribing opiates to addicts for self-administration (ambulatory treatment) was not an acceptable medical practice. For the next 50 years, opiate addiction was basically managed in this country by the criminal justice system and the two Federal Public Health Hospitals in Lexington, Kentucky, and Fort Worth, Texas. The relapse rate for opiate use from this approach was close to 100 percent. During the 1960s, opiate use reached epidemic proportions in the United States, spawning significant increases in crime and in deaths from opiate overdose. The increasing number of younger people entering an addiction lifestyle indicated that a major societal problem was emerging. This stimulated a search for innovative and more effective methods for treating the growing number of individuals dependent upon opiates. This search resulted in the emergence of drug-free therapeutic communities and the use of the opiate agonist methadone to maintain those with opiate dependence. Furthermore, a multimodality treatment strategy was designed to meet the needs of the individual addict patient. These three approaches remain the main treatment strategies being used to treat opiate dependence in the United States today.

Opiate dependence has long been associated with increased criminal activity. For example, in 1993 more than one-quarter of the inmates in State and Federal prisons were incarcerated for

drug offenses (234,600), and prisoners serving drug sentences were the largest single group (60 percent) in Federal prisons.

In the past 10 years, there has been a dramatic increase in the prevalence of human immunodeficiency virus (HIV), hepatitis B and C viruses, and tuberculosis among intravenous opiate users. From 1991 to 1995, in major metropolitan areas, the annual number of opiate-related emergency room visits increased from 36,000 to 76,000, and the annual number of opiate-related deaths increased from 2,300 to 4,000. This associated morbidity and mortality further underscore the human, economic, and societal costs of opiate dependence.

During the last two decades, evidence has accumulated on the neurobiology of opiate dependence. Whatever conditions may lead to opiate exposure, opiate dependence is a brain-related disorder with the requisite characteristics of a medical illness. Thus, opiate dependence as a medical illness will have varying causative mechanisms. There is a need to identify discrete subgroups of opiate-dependent persons and the most relevant and effective treatments for each subgroup. The safety and efficacy of narcotic agonist (methadone) maintenance treatment has been unequivocally established. Although there are other medications (e.g., levo-alpha acetylmethadol [LAAM] and naltrexone, an opiate antagonist) that are safe and effective in the treatment of opiate addicts, the focus of this consensus development conference was primarily on methadone maintenance treatment (MMT). MMT is effective in reducing illicit opiate drug use, in reducing crime, in enhancing social productivity, and in reducing the spread of viral diseases such as AIDS and hepatitis.

Approximately 115,000 of the estimated 600,000 opiate-dependent persons in the United States are in MMT. Science has not yet overcome the stigma of addiction and the negative public perception about MMT. Some leaders in the Federal Government, public health officials, members of the medical community, and the public at large frequently conceive of opiate dependence as a self-inflicted disease of the will or as a moral flaw. They also regard MMT as an ineffective

narcotic substitution and believe that a drug-free state is the only valid treatment goal. Other obstacles to MMT include Federal and State government regulations that restrict the number of treatment providers and patient access. Some of these Federal and State regulations are driven by disproportionate concerns about methadone diversion, concern about premature (e.g., in 12-year-olds) initiation of maintenance treatment, and concern about provision of methadone without any other psychosocial services.

Although a drug-free state represents an optimal treatment goal, research has demonstrated that this goal cannot be achieved or sustained by the majority of opiate-dependent people. However, other laudable treatment goals, including decreased drug use, reduced criminal activity, and gainful employment can be achieved by most MMT patients.

To address the most important issues surrounding effective medical treatment of opiate dependence, the NIH organized this 2½-day conference to present data on opiate agonist treatment for opiate dependence. The conference brought together national and international experts in the fields of the basic and clinical medical sciences, epidemiology, natural history, and prevention and treatment of opiate dependence, and broad representation from the public.

After 1½ days of presentations and audience discussion, an independent, non-Federal consensus panel, chaired by Lewis L. Judd, M.D., Mary Gilman Marston Professor, Chair of the Department of Psychiatry, University of California, San Diego School of Medicine, weighed the scientific evidence and wrote a draft statement that was presented to the audience on the third day. The consensus statement addressed the following key questions:

- What is the scientific evidence to support a conceptualization of opiate addiction as a medical disorder, including natural history, genetics and risk factors, and pathophysiology, and how is diagnosis established?

- What are the consequences of untreated opiate addiction to individuals, families, and society?
- What is the efficacy of current treatment modalities in the management of opiate addiction, including detoxification alone, nonpharmacological/psychosocial treatment, treatment with opiate antagonists, and treatment with opiate agonists (short term and long term)? And, what is the scientific evidence for the most effective use of opiate agonists in the treatment of opiate addiction?
- What are the important barriers to effective use of opiate agonists in the treatment of opiate addiction in the United States, including perceptions and the adverse consequences of opiate agonist use and legal, regulatory, financial, and programmatic barriers?
- What are the future research areas and recommendations for improving opiate agonist treatment and improving access?

What Is the Scientific Evidence to Support a Conceptualization of Opiate Dependence as a Medical Disorder, Including Natural History, Genetics and Risk Factors, and Pathophysiology, and How Is Diagnosis Established?

The Natural History of Opiate Dependence

Individuals addicted to opiates often become dependent on these drugs by their early twenties and remain intermittently dependent for decades. Biological, psychological, sociological, and economic factors determine when an individual will start taking opiates. However, it is clear that when use begins, it often escalates to abuse (repeated use with adverse consequences) and then to dependence (opioid tolerance, withdrawal symptoms, compulsive drug-taking). Once dependence is established, there are usually repeated cycles of cessation and relapse extending over decades. This “addiction career” is often accompanied by periods of imprisonment.

Treatment can alter the natural history of opiate dependence, most commonly by prolonging periods of abstinence from illicit opiate abuse. Of the various treatments available, MMT, combined with attention to medical, psychiatric, and socioeconomic issues, as well as drug counseling, has the highest probability of being effective.

Addiction-related deaths, including accidental overdose, drug-related accidents, and many illnesses directly attributable to chronic drug dependence explain one-fourth to one-third of the mortality in an opiate-addicted population. As a population of opiate addicts ages, there is a decrease in the percentage who are still addicted.

There is clearly a natural history of opiate dependence, but causative factors are poorly understood. It is especially unclear for a given individual whether repeated use begins as a medical disorder (e.g., a genetic predisposition) or whether socioeconomic and psychological factors lead an individual to try, and

then later to compulsively use, opiates. However, there is no question that once the individual is dependent on opiates, such dependence constitutes a medical disorder.

Molecular Neurobiology and Pathogenesis of Opiate Dependence: Genetic and Other Risk Factors for Opiate Dependence

Twin, family, and adoption studies show that vulnerability to drug abuse may be a partially inherited condition with strong influences from environmental factors. Cross-fostering adoption studies have demonstrated that both inherited and environmental factors operate in the etiology of drug abuse. These cross-fostering adoption studies identified two distinct genetic pathways to drug abuse/dependence. The first is a direct effect of substance abuse in a biologic parent. The second pathway is an indirect effect from antisocial personality disorder in a biologic parent, leading to both antisocial personality disorder and drug abuse/dependence in the adoptee. Family studies report significantly increased relative risk for substance abuse (6.7-fold increased risk), alcoholism (3.5), antisocial personality (7.6), and unipolar depression (5.1) among the first-degree relatives of opiate-dependent patients compared with relatives of controls. The siblings of opiate-dependent patients have very high susceptibility to abuse and dependence after initial use of illicit opioids. Twin studies indicate substantial heritability for substance abuse and dependence, with half the risk attributable to additive genetic factors.

Neurobiological Substrates of Opiate Dependence

Dopaminergic pathways from the ventral tegmentum (VT) to the nucleus accumbens (NA) and medial frontal cortex (MFC) are activated during rewarding behaviors. Opiates exert their rewarding properties by binding to the “mu” opioid receptor (OPRM) at several distinct anatomical locations in the brain, including the VT, NA, MFC, and possibly the locus coeruleus (LC). Opiate agonist administration causes inhibition of the LC. Chronic administration of opioid agonists causes adaptation to the LC inhibition. Rapid discontinuation of opioid agonists (or administration of antagonists) results in excessive LC

neuronal excitation and the appearance of withdrawal symptoms. Abnormal LC excitation is thought to underlie many of the physical symptoms of withdrawal, and this hypothesis is consistent with the ability of clonidine, an alpha-2 noradrenergic agonist, to ameliorate opiate withdrawal.

Regional Cerebral Glucose Metabolism in Opiate Abusers

Two independent human studies (using positron emission tomography) suggest that opiates reduce cerebral glucose metabolism in a global manner, with no regions showing increased glucose utilization. A third study demonstrates decreased D2 receptor availability in opiate-dependent patients compared with controls. Opiate antagonist administration produced an intense withdrawal experience but did not change D2 receptor availability.

Diagnosis of Opioid Dependence

Opioid dependence (addiction) is defined as a cluster of cognitive, behavioral, and physiological symptoms in which the individual continues use of opiates despite significant opiate-induced problems. Opioid dependence is characterized by repeated self-administration that usually results in opioid tolerance, withdrawal symptoms, and compulsive drug-taking. Dependence may occur with or without the physiological symptoms of tolerance and withdrawal. Usually, there is a long history of opioid self-administration, typically via intravenous injection in the arms or legs, although recently the intranasal route or smoking also is used. Often there is a history of drug-related crimes, drug overdoses, and family, psychological, and employment problems. There may be a history of physical problems, including skin infections, hepatitis, HIV infection, or irritation of the nasal and pulmonary mucosa. Physical examination usually reveals puncture marks along veins in the arms and legs and “tracks” secondary to sclerosis of veins. If the patient has not taken opiates recently, he or she may also demonstrate symptoms of withdrawal, including anxiety, restlessness, runny nose, tearing, nausea, and vomiting. Tests for opioids in saliva and urine can help

support a diagnosis of dependence. However, by itself, neither a positive nor a negative test can rule dependence in or out. Further evidence for opioid dependence can be obtained by a naloxone (Narcan) challenge test to induce withdrawal symptoms.

Evidence That Opioid Dependence Is a Medical Disorder

For decades, opioid dependence was viewed as a problem of motivation, willpower, or strength of character. Through careful study of its natural history and through research at the genetic, molecular, neuronal, and epidemiological levels, it has been proven that opiate addiction is a medical disorder characterized by predictable signs and symptoms. Other arguments for classifying opioid dependence as a medical disorder include:

- Despite varying cultural, ethnic, and socioeconomic backgrounds, there is clear consistency in the medical history, signs, and symptoms exhibited by individuals who are opiate-dependent.
- There is a strong tendency to relapse after long periods of abstinence.
- The opioid-dependent person's craving for opiates induces continual self-administration even when there is an expressed and demonstrated strong motivation and powerful social consequences to stop.
- Continuous exposure to opioids induces pathophysiologic changes in the brain.

What Are the Consequences of Untreated Opiate Dependence to Individuals, Families, and Society?

Of the estimated total opiate-dependent population of 600,000, only 115,000 are known to be in methadone maintenance treatment (MMT) programs. Research surveys indicate that the untreated population of opiate-addicted people is younger than those in treatment. They are typically in their late teens and early to middle twenties, during their formative, early occupational, and reproductive years. The financial costs of untreated opiate dependence to the individual, the family, and society are estimated to be approximately \$20 billion per year. The costs in human suffering are incalculable.

What is currently known about the consequences of untreated opiate dependence to individuals, families, and society?

Mortality

Before the introduction of MMT, annual death rates reported in four American studies of opiate dependence varied from 13 per 1,000 to 44 per 1,000, with a median of 21 per 1,000. Although it cannot be causally attributed, it is interesting to note that after the introduction of MMT, the death rates of opiate-dependent persons in four American studies had a narrower range, from 11 per 1,000 to 15 per 1,000, and a median of 13 per 1,000. The most striking evidence of the positive impact of MMT on death rates is studies directly comparing these rates in opiate-dependent persons, on and off methadone. Every study showed that death rates were lower in opiate-dependent persons maintained on methadone compared with those who were not. The median death rate for opiate-dependent persons in MMT was 30 percent of the death rate of those not in treatment. A clear consequence of not treating opiate dependence, therefore, is a death rate that is more than three times greater than that experienced by those engaged in MMT.

Illicit Drug Use

Multiple studies conducted over several decades and in different countries demonstrate clearly that MMT results in a marked decrease in illicit opiate use. In addition, there is also a significant and consistent reduction in the use of other illicit drugs, including cocaine and marijuana, and in the abuse of alcohol, benzodiazepines, barbiturates, and amphetamines.

Criminal Activity

Opiate dependence in the United States is unequivocally associated with high rates of criminal behavior. More than 95 percent of opiate-dependent persons report committing crimes during an 11-year at-risk interval. These crimes range in severity from homicides to other crimes against people and property. Stealing in order to purchase drugs is the most common criminal offense. Over the past two decades, clear and convincing evidence has been collected from multiple studies showing that effective treatment of opiate dependence markedly reduces the rates of criminal activity. Therefore, it is clear that significant amounts of crime perpetrated by opiate-dependent persons are a direct consequence of untreated opiate dependence.

Health Care Costs

Although the general health status of people with opiate dependence is substantially worse than that of their contemporaries, they do not routinely use medical services. Typically, they seek medical care in hospital emergency rooms only after their medical conditions are seriously advanced. The consequences of untreated opiate dependence include a much higher incidence of bacterial infections, including endocarditis, thrombophlebitis, and skin and soft tissue infections; tuberculosis; hepatitis B and C; AIDS and sexually transmitted diseases; and alcohol abuse. Because those who are opiate-dependent present for medical care late in their diseases, medical care is generally more expensive. Health care costs related to opiate dependence have been estimated to be \$1.2 billion per year.

Joblessness

Opiate dependence prevents many users from maintaining steady employment. Much of their time each day is spent in drug-seeking and drug-taking behavior. Therefore, many seek public assistance because they are unable to generate the income needed to support themselves and their families. Long-term outcome data show that opiate-dependent persons in MMT earn more than twice as much money annually as those not in treatment.

Outcomes of Pregnancy

A substantial number of pregnant women who are dependent on opiates also have HIV/AIDS. On the basis of preliminary data, women who receive MMT are more likely to be treated with zidovudine. It has been well established that administration of zidovudine to HIV-positive pregnant women reduces by two-thirds the rate of HIV transmission to their infants. Comprehensive MMT, along with sound prenatal care, has been shown to decrease obstetrical and fetal complications as well.

What Is the Efficacy of Current Treatment Modalities in the Management of Opiate Dependence, Including Detoxification Alone, Nonpharmacological/Psychosocial Treatment, Treatment With Opiate Antagonists, and Treatment With Opiate Agonists (Short Term and Long Term)? And, What Is the Scientific Evidence for the Most Effective Use of Opiate Agonists in the Treatment of Opiate Dependence?

The Pharmacology of Commonly Prescribed Opiate Agonists and Antagonists

The most frequently used agent in medically supervised opiate withdrawal and maintenance treatment is methadone. Methadone's half-life is approximately 24 hours and leads to a long duration of action and once-a-day dosing. This feature, coupled with its slow onset of action, blunts its euphoric effect, making it unattractive as a principal drug of abuse. LAAM, a less commonly used opiate agonist, has a longer half-life and may prevent withdrawal symptoms for up to 96 hours. An emerging treatment option, buprenorphine, a partial opioid agonist, appears also to be effective for detoxification and maintenance.

Naltrexone is a non-addicting specific "mu" antagonist with a long half-life, permitting once-a-day administration. It effectively blocks the cognitive and behavioral effects of opioids, and its prescription does not require special registration. The opioid-dependent person considering treatment should be informed of the availability of naltrexone maintenance treatment. However, in actively using opiate addicts, it produces immediate withdrawal symptoms with potentially serious effects.

Medically Supervised Withdrawal

Methadone can also be used for detoxification. This can be accomplished over several weeks after a period of illicit opiate use or methadone maintenance. If methadone withdrawal is too rapid, abstinence symptoms are likely. They may lead the opiate-dependent person to illicit drug use and relapse into another cycle of abuse. Buprenorphine holds promise as an option for medically supervised withdrawal because its prolonged occupation of “mu” receptors attenuates withdrawal symptoms.

More rapid detoxification options include use of opiate antagonists alone; the alpha-2 agonist clonidine alone; or clonidine followed by naltrexone. Clonidine reduces many of the autonomic signs and symptoms of opioid withdrawal. These strategies may be used in both inpatient and outpatient settings and allow medically supervised withdrawal from opioids in as little as 3 days. Most patients successfully complete detoxification using these strategies, but information concerning relapse rates is not available.

The Role of Psychosocial Treatments

Nonpharmacologic supportive services are pivotal to successful MMT. The immediate introduction of these services as the opiate-dependent patient applies for MMT leads to significantly higher retention and more comprehensive and effective treatment. Comorbid psychiatric disorders require treatment. Other behavioral strategies have been successfully used in substance abuse treatment. Ongoing substance abuse counseling and other psychosocial therapies enhance program retention and positive outcome. Stable employment is an excellent predictor of clinical outcome. Therefore, vocational rehabilitation is a useful adjunct.

Efficacy of Opiate Agonists

It is now generally agreed that opiate dependence is a medical disorder and that pharmacologic agents are effective in its treatment. Evidence presented to the panel indicates

that availability of these agents is severely limited and that large numbers of patients with this disorder have no access to treatment.

The greatest experience with such agents has been with the opiate agonist methadone. Prolonged oral treatment with this medication diminishes and often eliminates opiate use, reduces transmission of many infections, including HIV and hepatitis B and C, and reduces criminal activity. Evidence is now accumulating suggesting that LAAM and buprenorphine are effective in such patients.

For more than 30 years, the daily oral administration of methadone has been used to treat tens of thousands of individuals dependent upon opiates in the United States and abroad. The effectiveness of MMT is dependent on many factors, including adequate dosage, duration plus continuity of treatment, and accompanying psychosocial services. A dose of 60 mg given once daily may achieve the desired treatment goal: abstinence from opiates. But higher doses are often required by many patients. Continuity of treatment is crucial—patients who are treated for fewer than 3 months generally show little or no improvement, and most, if not all, patients require continuous treatment over a period of years and perhaps for life. Therefore, the program has come to be termed methadone “maintenance” treatment (MMT). Patient attributes that have sometimes been linked to better outcomes include older age, later age of dependence onset, less abuse of other substances including cocaine and alcohol, and less criminal activity. Recently, it has been reported that high motivation for change has been associated with positive outcomes.

The effectiveness of MMT is often dependent on the involvement of a knowledgeable and empathetic staff and the availability of psychotherapy and other counseling services.

The latter are especially important since individuals with opiate dependence are often afflicted with comorbid mental and personality disorders.

Because methadone-treated patients generally are exposed to much less or no intravenous opiates, they are much less likely to transmit and contract HIV and hepatitis. This is especially important since recent data have shown that up to 75 percent of new instances of HIV infection are attributable to intravenous drug use. Since for many patients a major source of financing the opiate habit is criminal behavior, MMT generally leads to much less crime.

Although methadone is the primary opioid agonist used, other full and partial opioid agonists have been developed for treatment of opiate dependence. An analogue of methadone, levo-alpha acetylmethadol (LAAM), has a longer half-life than methadone and therefore can be administered less frequently. A single dose of LAAM can prevent withdrawal symptoms and drug craving for 2 to 4 days. Buprenorphine, a recently developed partial opiate agonist, has an advantage over methadone; its discontinuation leads to much less severe withdrawal symptoms. The use of these medications is at an early stage, and it may be some time before their usefulness has been adequately evaluated.

What Are the Important Barriers to Effective Use of Opiate Agonists in the Treatment of Opiate Addiction in the United States, Including Perceptions and the Adverse Consequences of Opiate Agonist Use and Legal, Regulatory, Financial, and Programmatic Barriers?

Misperceptions and Stigmas

Many of the barriers to effective use of MMT in the treatment of opiate dependence stem from misperceptions and stigmas attached to opiate dependence, the people who are addicted, those who treat them, and the settings in which services are provided. Opiate-dependent persons are often perceived not as individuals with a disease but as “other” or “different.” Factors such as racism play a large role here but so does the popular image of dependence itself. Many people believe that dependence is self-induced or a failure of willpower and that efforts to treat it will inevitably fail. Vigorous and effective leadership is needed to inform the public that dependence is a medical disorder that can be effectively treated with significant benefits for the patient and society.

Increasing Availability of Effective Services

Unfortunately, MMT programs are not readily available to all who could and wish to benefit from them. We as a society must make a commitment to offering effective treatment for opiate dependence to all who need it. Accomplishing that goal will require:

- Making treatment as cost-effective as possible without sacrificing quality.
- Increasing the availability and variety of treatment services.
- Including and ensuring wider participation by physicians trained in substance abuse who will oversee the medical care.

- Providing additional funding for opiate dependence treatments and coordinating these services with other necessary social services and medical care.

Training Physicians and Other Health Care Professionals

One barrier to availability of MMT is the shortage of physicians and other health care professionals prepared to provide treatment for opiate dependence. Practitioners of all primary care medical specialties (including general practice, internal medicine, family practice, obstetrics and gynecology, geriatrics, pediatrics, and adolescent medicine) should be taught the principles of diagnosing and treating patients with opiate dependence. Nurses, social workers, psychologists, physician assistants, and other health care professionals should also be trained in these areas. The greater the number of trained physicians and other health care professionals, the greater the supply not only of professionals who can competently treat the opiate dependent but also of members of the community who are equipped to provide leadership and public education on these issues.

Reducing Unnecessary Regulation

Of critical importance in improving MMT of opiate dependence is the recognition that, as in every other area of medicine, treatment must be tailored to the needs of the individual patient. Current Federal regulations make this difficult if not impossible. By prescribing MMT procedures in minute detail, FDA's regulations limit the flexibility and responsiveness of the programs, require unproductive paperwork, and impose administrative and oversight costs greater than those necessary for many patients. Yet these regulations seem to have little if any effect on quality of MMT care. We know of no other area where the Federal Government intrudes so deeply and coercively into the practice of medicine. For example, although providing a therapeutic dose is central to effective treatment and the therapeutic dose is now known to be higher than had previously been understood, FDA's regulations discourage such higher doses. However well intended the FDA's

treatment regulations were when written in 1972, they are no longer helpful. We recommend that these regulations be eliminated. Alternative means, such as accreditation, for improving quality of MMT programs should be instituted. The U.S. Department of Health and Human Services can more effectively, less coercively, and much less expensively discharge its statutory obligation to provide treatment guidance to MMT programs, physicians, and staff by means of publications, seminars, Web sites, continuing medical education, and the like.

We also believe current laws and regulations should be revised to eliminate the extra level of regulation on methadone compared with other Schedule II narcotics. Currently, methadone can be dispensed only from facilities that obtain an extra license and comply with extensive extra regulatory requirements. These extra requirements are unnecessary for a medication that is not often diverted to individuals for recreational or casual use but rather to individuals with opiate dependence who lack access to MMT programs.

If extra levels of regulation were eliminated, many more physicians and pharmacies could prescribe and dispense methadone, making treatment available in many more locations than is now the case. Not every physician will choose to treat opiate-dependent persons, and not every methadone-treated person will prefer to receive services from an individual physician rather than to receive MMT in a clinic setting. But if some additional physicians and groups treat a few patients each, aggregate access to MMT would be expanded.

We also believe that State and local regulations and enforcement efforts should be coordinated. We see little reason for separate State and Federal inspections of MMT programs. State and Federal regulators should coordinate their efforts, agree about which programs each will inspect to avoid duplication, and target “poor performers” for the most intensive scrutiny while reducing scrutiny for MMT programs that consistently perform well. The States should address the

problem of slow approval (at the State level) of FDA-approved medications. LAAM, for example, has not yet been approved by many States. States should harmonize their requirements with those of the Federal Government.

We would expect these changes in the current regulatory system to reduce unnecessary costs both to MMT programs and to enforcement agencies at all levels. The savings could be used to treat more patients.

In the end, an infusion of additional funding will be needed—funding sufficient to provide access to treatment for all who require treatment. We strongly recommend that legislators and regulators recognize that providing MMT is both cost-effective and compassionate and that it constitutes a health benefit that should be a component of public and private health care.

What Are the Future Research Areas and Recommendations for Improving Opiate Agonist Treatment and Improving Access?

- What initiates opiate use?
- Define genetic predispositions.
- Do some individuals take opiates to treat a preexisting disorder?
- Which of the multiple psychological, sociological, and economic factors believed to predispose individuals to try opiates are most important as causative factors?
- If the above are known, can one prevent opiate dependence?
- What are the changes in the human brain that result in dependence when individuals repeatedly use opiates?
- What are the underlying anatomical and neurophysiological substrates of craving?
- What are the differences between individuals who can successfully terminate opiate dependence and those who cannot?
- A scientifically credible national epidemiological study of the prevalence of opiate dependence in the United States is strongly recommended.
- Rigorous study of the economic costs of opiate dependence in the United States and the cost-effectiveness of methadone maintenance therapy is also needed.
- Longer term followup studies of patients who complete rapid detoxification are necessary.
- The feasibility of alternative routes of administration for agonist and antagonist therapy should be explored.

- Systematic pharmacokinetic studies of methadone during MMT maintenance therapy are essential.
- Physiologic factors that may influence adequate methadone dose in pregnant women need to be defined.
- The effects of reduction of entitlement programs for those patients on MMT must be assessed.
- The effects of the early and systematic introduction of rehabilitation services in MMT should be evaluated.
- Variables that determine barriers must be defined.
- Research on changing attitudes of the public, of health professionals, and of legislators is needed.
- Research on improving educational methods for health professionals should be performed.
- Research on prevention methods is necessary.
- Research on efficacy of other opiate agonists/antagonists should be compared with that of methadone.

Conclusions and Recommendations

- Vigorous and effective leadership is needed within the Office of National Drug Control Policy (ONDCP) (and related Federal and State agencies) to inform the public that dependence is a medical disorder that can be effectively treated with significant benefits for the patient and society.
- Society must make a commitment to offering effective treatment for opiate dependence to all who need it.
- The panel calls attention to the need for opiate-dependent persons under legal supervision to have access to MMT. The ONDCP and the U.S. Department of Justice should implement this recommendation.
- The panel recommends improved training of physicians and other health care professionals in diagnosis and treatment of opiate dependence. For example, we encourage the National Institute on Drug Abuse and other agencies to provide funds to improve training for diagnosis and treatment of opiate dependence in medical schools.
- The panel recommends that unnecessary regulation of MMT and all long-acting agonist treatment programs be reduced.
- Funding for MMT should be increased.
- We advocate MMT as a benefit in public and private insurance programs, with parity of coverage for all medical and mental disorders.
- We recommend targeting opiate-dependent pregnant women for MMT.
- MMT must be culturally sensitive to enhance a favorable outcome for participating African American and Hispanic persons.
- Patients, underrepresented minorities, and consumers should be included in bodies charged with policy development guiding opiate dependence treatment.
- We recommend expanding the availability of opiate agonist treatment in those States and programs where this treatment option is currently unavailable.

Consensus Development Panel

Lewis L. Judd, M.D.

*Conference and Panel Chair
Mary Gilman Marston Professor
and Chair*
Department of Psychiatry
School of Medicine
University of California,
San Diego
La Jolla, California

Clifford Attkisson, Ph.D.

*Dean of Graduate Studies
Associate Vice Chancellor for
Student Academic Affairs
Professor of Medical Psychology*
University of California,
San Francisco
San Francisco, California

Wade Berrettini, M.D., Ph.D.

*Professor of Psychiatry
and Director*
Center for Neurobiology
and Behavior
Department of Psychiatry
School of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania

Nancy L. Buc, Esq.

Buc & Beardsley
Washington, D.C.

Benjamin S. Bunney, M.D.

*Charles B.G. Murphy Professor
and Chairman*
Professor of Pharmacology
Department of Psychiatry
Yale University School
of Medicine
New Haven, Connecticut

Roberto A. Dominguez, M.D.

*Professor and Director of
Adult Outpatient Clinic*
Department of Psychiatry
University of Miami
School of Medicine
Miami, Florida

Robert O. Friedel, M.D.

*Heman E. Drummond Professor
and Chairman*
Department of Psychiatry and
Behavioral Neurobiology
The University of Alabama
at Birmingham
Birmingham, Alabama

John S. Gustafson

Executive Director
National Association of State
Alcohol and Drug Abuse
Directors, Inc.
Washington, D.C.

Donald Hedeker, Ph.D.

*Associate Professor of
Biostatistics*
Division of Epidemiology
and Biostatistics
School of Public Health
University of Illinois, Chicago
Chicago, Illinois

Howard H. Hiatt, M.D.

Professor of Medicine
Harvard Medical School
Senior Physician
Division of General Medicine
Brigham and Women's Hospital
Boston, Massachusetts

Radman Mostaghim, M.D., Ph.D.

Greenbelt, Maryland

Robert G. Petersdorf, M.D.

*Distinguished Professor
of Medicine*

University of Washington

Seattle, Washington

Speakers

M. Douglas Anglin, Ph.D.

“The Natural History of
Opiate Addiction”

Director

UCLA Drug Abuse
Research Center
Los Angeles, California

Donald C. Des Jarlais, Ph.D.

“Transmission of Bloodborne
Viruses Among Heroin
Injectors”

Director of Research

Chemical Dependency Institute
Beth Israel Medical Center and
National Development and
Research Institutes
New York, New York

David P. Desmond, M.S.W.

“Deaths Among Heroin Users
In and Out of Methadone
Maintenance”

Instructor

Department of Psychiatry
University of Texas
Health Science Center
San Antonio, Texas

Rose Etheridge, Ph.D.

“Factors Related to Retention
and Posttreatment Out-
comes in Methadone
Treatment: Replicated
Findings Across Two
Eras of Treatment”

Senior Research Psychologist

National Development and
Research Institutes, Inc.
(NDRI, Inc.)
Raleigh, North Carolina

Igor I. Galynker, M.D., Ph.D.

“Methadone Maintenance and
Regional Cerebral Glucose
Metabolism in Opiate
Abusers: A Positron Emission
Tomographic Study”

Physician-in-Charge

Division of Psychiatric
Functional Brain Imaging
Department of Psychiatry
Beth Israel Medical Center
New York, New York

G. Thomas Gitchel

“Diversion of Methadone:
Expanding Access While
Reducing Abuse”

Chief

Liaison and Policy Section
Office of Diversion Control
U.S. Drug Enforcement
Administration
Washington, D.C.

Michael Gossop, Ph.D.

“Methadone Substitution Treat-
ment in the United Kingdom:
Outcome Among Patients
Treated in Drug Clinics and
General Practice Settings”

Head of Research

National Addiction Centre
Institute of Psychiatry
Maudsley Hospital
London, United Kingdom

John Grabowski, Ph.D.

“Behavioral Therapies:
A Treatment Element
for Opiate Dependence”

Director

Substance Abuse Research
Center

Professor

Department of Psychiatry
Health Science Center
University of Texas, Houston
Houston, Texas

Henrick J. Harwood

“Societal Costs of Heroin
Addiction”
Senior Manager
The Lewin Group
Fairfax, Virginia

Jerome H. Jaffe, M.D.

“The History and Current Status
of Opiate Agonist Treatment”
Director
Office for Scientific Analysis
and Evaluation
Center for Substance Abuse
Treatment
Substance Abuse and Mental
Health Services Administration
Rockville, Maryland

Herbert D. Kleber, M.D.

“Detoxification With or Without
Opiate Agonist Treatment”
Professor of Psychiatry
Division of Substance Abuse
Department of Psychiatry
Columbia University College of
Physicians and Surgeons
New York, New York

Mary Jeanne Kreek, M.D.

“Opiate Agonist Treatment,
Molecular Pharmacology,
and Physiology”
Professor and Head
Senior Physician
Laboratory of the Biology
of Addictive Diseases
Rockefeller University
New York, New York

David C. Lewis, M.D.

“Access to Narcotic Addiction
Treatment and Medical Care”
Director
Center for Alcohol and
Addiction Studies
Brown University
Providence, Rhode Island

Dennis McCarty, Ph.D.

“Narcotic Agonist Treatment
as a Benefit Under
Managed Care”
Human Services Research
Professor
Institute for Health Policy
Heller Graduate School
Brandeis University
Waltham, Massachusetts

A. Thomas McLellan, Ph.D.

“Problem-Service Matching in
Methadone Maintenance
Treatment: Policy Sugges-
tions From Two Prospective
Studies”
Scientific Director
DeltaMetrics in Association With
Treatment Research Institute
Philadelphia, Pennsylvania

Jeffrey Merrill, Ph.D.

“Impact of Methadone Mainte-
nance on HIV Seroconversion
and Related Costs”
Director
Economic and Policy Research
Treatment Research Institute
University of Pennsylvania
Philadelphia, Pennsylvania

Eric J. Nestler, M.D., Ph.D.

“Neurobiological Substrates
for Opiate Addiction”
Elizabeth Mears and House
Jameson Professor of
Psychiatry and Pharmacology
Department of Psychiatry
Connecticut Mental Health
Center
Yale University School
of Medicine
New Haven, Connecticut

David N. Nurco, D.S.W.

“Narcotic Drugs and Crime:
Addict Behavior While
Addicted Versus
Nonaddicted”

Research Professor
Department of Psychiatry
University of Maryland
School of Medicine
Baltimore, Maryland

Mark W. Parrino, M.P.A.

“Legal, Regulatory, and Funding
Barriers to Good Practice and
Associated Consequences”

President
American Methadone Treatment
Association, Inc.
New York, New York

J. Thomas Payte, M.D.

“Methadone Dose and Outcome”
Medical Director
Drug Dependence Associates
San Antonio, Texas

Roy W. Pickens, Ph.D.

“Genetic and Other Risk Factors
in Opiate Addiction”

Senior Scientist
Division of Intramural Research
Addiction Research Center
National Institute on Drug Abuse
National Institutes of Health
Baltimore, Maryland

D. Dwayne Simpson, Ph.D.

“Patient Engagement and
Duration of Treatment”

Director and S.B. Sells
Professor of Psychology
Institute of Behavioral Research
Texas Christian University
Fort Worth, Texas

Barbara J. Turner, M.D.

“Prenatal Care and Antiretro-
viral Use Associated With
Methadone Treatment of
HIV-Infected Pregnant
Women”

Professor of Medicine
Director of Research in
Health Care
Thomas Jefferson University
The Center for Research in
Medical Education and
Health Care
Philadelphia, Pennsylvania

George E. Woody, M.D.

“Establishing a Diagnosis
of Heroin Abuse
and Addiction”

Chief, Substance Abuse
Treatment Unit
Veterans Affairs Medical Center
Clinical Professor
Department of Psychiatry
University of Pennsylvania
Philadelphia, Pennsylvania

Joan E. Zweben, Ph.D.

“Community, Staff, and Patient
Perceptions and Attitudes”

Executive Director
14th Street Clinic and
East Bay Community
Recovery Project
Clinical Professor of Psychiatry
University of California,
San Francisco
Berkeley, California

Planning Committee

James R. Cooper, M.D.

*Associate Director for
Medical Affairs*
Division of Clinical and
Services Research
National Institute on Drug Abuse
National Institutes of Health
Rockville, Maryland

Elsa A. Bray

Program Analyst
Office of Medical Applications
of Research
National Institutes of Health
Bethesda, Maryland

Mona Brown

Press Officer
National Institute on Drug Abuse
National Institutes of Health
Rockville, Maryland

Kendall Bryant, Ph.D.

Coordinator
AIDS Behavioral Research
National Institute on Alcohol
Abuse and Alcoholism
National Institutes of Health
Rockville, Maryland

Jerry Cott, Ph.D.

Chief
Pharmacologic Treatment
Research Program
National Institute of
Mental Health
National Institutes of Health
Rockville, Maryland

Donald C. Des Jarlais, Ph.D.

Director of Research
Chemical Dependency Institute
Beth Israel Medical Center and
National Development and
Research Institutes
New York, New York

John H. Ferguson, M.D.

Director
Office of Medical Applications
of Research
National Institutes of Health
Bethesda, Maryland

Bennett Fletcher, Ph.D.

Acting Chief
Services Research Branch
Division of Clinical and
Services Research
National Institute on Drug Abuse
National Institutes of Health
Rockville, Maryland

Joseph Frascella, Ph.D.

Chief
Etiology and Clinical
Neurobiology Branch
Division of Clinical and
Services Research
National Institute on Drug Abuse
National Institutes of Health
Rockville, Maryland

G. Thomas Gitchel

Chief
Liaison and Policy Section
Office of Diversion Control
U.S. Drug Enforcement
Administration
Washington, D.C.

William H. Hall

Director of Communications
Office of Medical Applications
of Research
National Institutes of Health
Bethesda, Maryland

Jerome H. Jaffe, M.D.

Director
Office for Scientific Analysis
and Evaluation
Center for Substance
Abuse Treatment
Substance Abuse and
Mental Health Services
Administration
Rockville, Maryland

Lewis L. Judd, M.D.

Panel and Conference Chair
Mary Gilman Marston
Professor and Chair
Department of Psychiatry
School of Medicine
University of California,
San Diego
La Jolla, California

Herbert D. Kleber, M.D.

Professor of Psychiatry
Division of Substance Abuse
Department of Psychiatry
Columbia University
College of Physicians
and Surgeons
New York, New York

Mitchell B. Max, M.D.

Chief
Clinical Trials Unit
Neurobiology and
Anesthesiology Branch
National Institute of Dental
Research
National Institutes of Health
Bethesda, Maryland

A. Thomas McLellan, Ph.D.

Scientific Director
DeltaMetrics in Association
With Treatment Research
Institute
Philadelphia, Pennsylvania

Eric J. Nestler, M.D., Ph.D.

Elizabeth Mears and House
Jameson Professor of
Psychiatry and Pharmacology
Department of Psychiatry
Connecticut Mental Health
Center
Yale University School
of Medicine
New Haven, Connecticut

Stuart Nightingale, M.D.

Associate Commissioner
for Health Affairs
U.S. Food and Drug
Administration
Rockville, Maryland

Roy W. Pickens, Ph.D.

Senior Scientist
Division of Intramural Research
Addiction Research Center
National Institute on Drug Abuse
National Institutes of Health
Baltimore, Maryland

Nick Reuter, M.P.H.

Associate Director for Domestic
and International Drug Control
U.S. Food and Drug
Administration
Rockville, Maryland

Charles R. Sherman, Ph.D.

Deputy Director
Office of Medical Applications
of Research
National Institutes of Health
Bethesda, Maryland

Alan Trachtenberg, M.D., M.P.H.

Medical Officer
Office of Science Policy and
Communications
National Institute on Drug Abuse
National Institutes of Health
Rockville, Maryland

Frank Vocci, Ph.D.

Acting Director

Medications Development
Division

National Institute on Drug Abuse
National Institutes of Health
Rockville, Maryland

Anne Willoughby, M.D., M.P.H.

Chief

Pediatric, Adolescent, and
Maternal AIDS Branch
Center for Research for Mothers
and Children
National Institute of Child Health
and Human Development
National Institutes of Health
Rockville, Maryland

Stephen R. Zukin, M.D.

Director

Division of Clinical and
Services Research
National Institute on Drug Abuse
National Institutes of Health
Rockville, Maryland

Lead Organizations

National Institute on Drug Abuse

Alan I. Leshner, Ph.D.
Director

Office of Medical Applications of Research

John H. Ferguson, M.D.
Director

Supporting Organizations

Office of Research on Women's Health

Vivian W. Pinn, M.D.
Director

Bibliography

The speakers listed above identified the following key references in developing their presentations for the consensus conference. A more complete bibliography prepared by the National Library of Medicine at NIH, along with the references below, was provided to the consensus panel for their consideration. The full NLM bibliography is available at the following Web site: http://www.nlm.nih.gov/pubs/cbm/heroin_addiction.html.

Overview and Natural History

Anglin MD, Hser Y. Treatment of drug abuse. In: Tonry M, Wilson JQ, editors. *Drugs and crime*. Chicago: University of Chicago Press; 1990. p. 393-458.

Cooper JR. Methadone treatment and acquired immunodeficiency syndrome. *JAMA* 1989;252:1664-8.

Courtwright DT. A century of American narcotic policy. In: Gerstein DR, Harwood HJ, editors. *Treating drug problems*. Vol. 2. Institute of Medicine. Washington: National Academy Press; 1992.

Dole, VP. Hazards of process regulations: the example of methadone maintenance. *JAMA* 1992;267:2234-5.

Gerstein DR, Harwood HJ, editors. *Treating drug problems*. Vol. 1. Institute of Medicine. Washington: National Academy Press; 1990.

Hser Y, Anglin MD, Grell C, Longshore D, Prendergast M. Drug treatment careers: a conceptual framework and existing research findings. *J Subst Abuse* 1997;14(3):1-16.

Hser Y, Anglin MD, Powers K. A 24-year follow-up of California narcotics addicts. *Arch Gen Psychiatry* 1993;50:577-84.

Hser Y, Yamaguchi K, Anglin MD, Chen J. Effects of interventions on relapse to narcotics addiction. *Eval Rev* 1995;19:123-40.

Molinari SP, Cooper JR, Czechowicz DJ. Federal regulation of clinical practice in narcotic addiction treatment: purpose, status, and alternatives. *J Law Med Ethics* 1994;22(3):231-9.

Musto DF. *The American disease. Origins of narcotic control*. Expanded edition. New York: Oxford University Press; 1987.

Rettig RA, Yarmolinsky A, editors. *Federal regulation of methadone treatment*. Institute of Medicine. Washington: National Academy Press; 1995.

Molecular Neurobiology and Pathogenesis of Opiate Addiction

Cadore R, Troughton E, O'Gorman TW, Heywood E. An adoption study of genetic and environmental factors in drug abuse. *Arch Gen Psychiatry* 1986;43:1131-6.

Goldstein A. Heroin addiction: neurobiology, pharmacology, and policy. *J Psychoactive Drugs* 1991 Apr;23(2):123-33.

Krystal JH, Woods SW, Kosten TR, Rosen MI, Seibyl JP. Opiate dependence and withdrawal: preliminary assessment using single photon emission computerized tomography (SPECT). *Am J Drug Alcohol Abuse* 1995 Feb;21(1):47-63.

London ED, Broussolle EP, Links JM, Wong DF, Cascella NG, Dannals RF, et al. Morphine-induced metabolic changes in human brain. Studies with positron emission tomography and [fluorine 18]fluorodeoxyglucose. *Arch Gen Psychiatry* 1990 Jan;47 (1):73-81.

Merikangas KR, Rounsaville BJ, Prusoff BA. Familial factors in vulnerability to substance abuse. In: Glantz M, Pickens R, editors. *Vulnerability to drug abuse*. Washington: American Psychological Association; 1992. p. 75-97.

Nestler EJ. Under seige: the brain on opiates. *Neuron* 1996;16:897-900.

Pickens RW, Svikiel DS, McGue M, Lykken DT, Heston LL, Clayton PJ. Heterogeneity in the inheritance of alcoholism. A study of male and female twins. *Arch Gen Psychiatry* 1991 Jan;48(1):19-28.

Tsuang MT, Lyons MJ, Eisen SA, Goldberg J, True W, Lin N, et al. Genetic influences on DSM-III-R drug abuse and dependence: a study of 3,372 twin pairs. *Am J Med Genet* 1996;67:473-7.

Walsh SL, Gilson SF, Jasinski DR, Stapleton JM, Phillips RL, Dannals RF, et al. Buprenorphine reduces cerebral glucose metabolism in polydrug abusers. *Neuropsychopharmacology* 1994 May;10(3):157-70.

Consequences of Untreated Opiate Addiction

Barrett DH, Luk AJ, Parrish RG, Jones TS. An investigation of medical examiner cases in which methadone was detected, Harris County, Texas, 1987-1992. *J Forensic Sci* 1996 May;41(3):442-8.

Caplehorn JR, Dalton MS, Haldar F, Petrenas AM, Nisbet JG. Methadone maintenance and addicts' risk of fatal heroin overdose. *Subst Use Misuse* 1996 Jan;31(2):177-96.

Des Jarlais DC. Research design, drug use, and deaths: cross study comparisons. In: Serban G, editor. *The social and medical aspects of drug abuse*. Jamaica (NY): Spectrum Publications; 1984. p. 229-35.

Edwards G, Gross MM. Alcohol dependence: provisional description of a clinical syndrome. *Br Med* 1996;1:1058-61.

Frances A, Pincus HA, First MB, editors. Substance related disorders. In: *Diagnostic and statistical manual of mental disorders*. 4th ed. (DSM-IV). Washington: American Psychiatric Association Press; 1994. p. 175-272.

Grönbladh L, Öhlund LS, Gunne LM. Mortality in heroin addiction: impact of methadone treatment. *Acta Psychiatr Scand* 1990 Sep;82(3):223-7.

Nurco DN, Ball JC, Shaffer JW, Hanlon TE. The criminality of narcotic addicts. *J Nerv Ment Dis* 1985;173:94-102.

Nurco DN, Cisin IH, Balter MB. Addicts career II: the first ten years. *Addict* 1981;8:1327-56.

Nurco DN, Hanlon TE, Balter MB, Kinlock TW, Slaughter E. A classification of narcotic addicts based on type, amount, and severity of crime. *J Drug Issues* 1991;21:429-48.

Nurco DN, Shaffer JW, Ball JC, Kinlock TW. Trends in the commission of crime among narcotic addicts over successive periods of addiction and nonaddiction. *Am J Drug Alcohol Abuse* 1984;10:481-9.

Current Opiate Addiction Treatment Modalities

Cooper JR. Establishing a methadone quality assurance system: rationale and objectives. In: *Improving drug abuse treatment*. National Institute on Drug Abuse Research Monograph Series #106. Washington: DHHS; 1991. p. 358-64.

Elk R, Grabowski J, Rhoades HM, McLellan AT. A substance abuse research-treatment clinic. *Substance Abuse Treatment*. 1993;10(5): 459-71.

Gossop M, Griffiths P, Bradley B, Strang J. Opiate withdrawal symptoms in response to 10-day and 21-day methadone withdrawal programmes. *Br J Psychiatry* 1989;154:360-3.

Kleber HD. Outpatient detoxification from opiates. *Primary Psychiatry* 1996;1:42-52.

Kosten TR, Morgan C, Kleber HD. Treatment of heroin addicts using buprenorphine. *Am J Drug Alcohol Abuse* 1991;7(1):119-28.

Rhoades H, Creson D, Elk R, Schmitz J, Grabowski J. Retention, HIV risk, and illicit drug use during treatment: methadone dose and visit frequency. *Am J Public Health* 1997;88:34-9.

Senay EC, Barthwell AG, Marks R, Boros P, Gillman D, White G. Medical maintenance: a pilot study. *J Addict Dis* 1993;12(4):59-76.

Vining E, Kosten TR, Kleber HD. Clinical utility of rapid clonidine-naltrexone detoxification for opioid abuse. *Br J Addict* 1988; 83:567-75.

Predictors of Treatment Outcome

Ball JC, Ross A. The effectiveness of methadone maintenance treatment. New York: Springer Verlag; 1991.

Dole VP. Implications of methadone maintenance for theories of narcotic addiction. *JAMA* 1988;260(20):3025-9.

Etheridge RM, Craddock SG, Duntelman GH, Hubbard RL. Treatment services in two national studies of community-based drug abuse treatment programs. *J Subst Abuse Treat* 1995;7:9-26.

Grudzinskas CV, Woosley RL, Payte JT, Collins J, Moody DE, Tyndale RF, et al. The documented role of pharmacogenetics in the identification and administration of new medications for treatment of drug abuse. Problems of drug dependence 1995: Proceedings of the 57th Annual Scientific Meeting. NIDA research monograph; 1995. p. 60-3.

Hubbard RL, Craddock SG, Flynn PM, Anderson J, Etheridge RM. Overview of one-year followup outcomes in DATOS. *Psychology of Addictive Behaviors* 1997;11(4).

Hubbard RL, Marsden ME, Rachal JV, Harwood HJ, Cavanaugh ER, Ginzburg HM. Drug abuse treatment: a national study of effectiveness. Chapel Hill: The University of North Carolina Press; 1995.

Joe GW, Simpson DD, Sells SB. Treatment process and relapse to opioid use during methadone maintenance. *Am J Drug Alcohol Abuse* 1994;20(2):173-97.

Loimer N, Schmid R, Grünberger J, Jagsch R, Linzmayer L, Presslich O. Psychophysiological reactions in methadone maintenance patients do not correlate with methadone plasma levels. *Psychopharmacology* 1991;103:538-40.

McLellan AT, Alterman AI, Metzger DS, Grissom G, Woody GE, Luborsky L, et al. Similarity of outcome predictors across opiate, cocaine and alcohol treatments: role of treatment services. *J Consult Clin Psychol* 1994;62:1141-58.

McLellan AT, Arndt IO, Alterman AI, Woody GE, Metzger D. Psychosocial services in substance abuse treatment: a dose-ranging study of psychosocial services. *JAMA* 1993.

McLellan AT, Woody GE, Luborsky L, O'Brien CP. Is the counselor an "active ingredient" in substance abuse treatment? *J Nerv Ment Dis* 1988;176(7):423-30.

National evaluations of drug abuse treatment outcomes. *Psych Addict Behav* [Special Issue]. In press.

Simpson DD. Effectiveness of drug-abuse treatment: a review of research from field settings. In: Egertson JA, Fox DM, Leshner AI, editors. *Treating drug abusers effectively*. Cambridge, MA: Blackwell Publishers of North America; 1997. p. 42-73.

Simpson DD, Joe GW, Dansereau DF, Chatham LR. Strategies for improving methadone treatment process and outcomes. *J Drug Issues* 1997;27(2):239-60.

Tennant FS, Rawson RA, Cohen A, Tarver A, Clabout C. Methadone plasma levels and persistent drug abuse in high dose maintenance patients. *Subst Alcohol Actions Misuse* 1983;4:369-74.

Yancovitz SR, Des Jarlais DC, Peyser NP, Drew E, Friedmann P, Trigg HL, et al. *Am J Public Health* 1991;81(9):1185-91.

Barriers to Effective Use and Availability of Opiate Agonist Treatment

Anglin MD, Speckart GR, Booth MW, Ryan TM. Consequences and costs of shutting off methadone. *Addict Behav* 1989;14:307-26.

Caplehorn JR, Hartel DM, Irwig L. Measuring and comparing the attitudes and beliefs of staff working in New York methadone maintenance clinics. *Subst Use Misuse* 1997;32(4):399-413.

Cooper JR. Including narcotic addiction treatment in an office-based practice. *JAMA* 1995a;273:1619-20.

Dole VP. On federal regulation of methadone treatment. *Conn Med* 1996;60:428-9.

Institute of Medicine. *Managing managed care: quality improvement in behavioral health*. Washington: National Academy Press; 1997.

Lewis D, Gear C, Laubli Loud M, Langenick-Cartwright D, English edition editors. *The medical prescription of narcotics*, Rihs-Middel M, editor. Toronto: Hogrefe & Huber Publishers; 1997.

Mechanic D, Schlesinger M, McAlpine DD. Management of mental health and substance abuse services: state-of-the-art and early results. *Milbank Q* 1995;73:19-55.

Murphy S, Irwin J. "Living with the dirty secret": Problems of disclosure for methadone maintenance clients. *J Psychoactive Drugs* 1992;24(3):257-64.

Novick M, Joseph H, Salsitz EA, Kalin MF, Keefe JB, Miller EL, et al. Outcomes of treatment of socially rehabilitated methadone maintenance patients in physicians' offices (medical maintenance): follow-up at three and a half to nine and a fourth years. *J Gen Intern Med* 1994;9:127-30.

Rogowski JA. Insurance coverage for drug abuse. *Health Aff* 1992; 11(3):137-48.

Scott JE, Greenberg D, Pizzaro J. A survey of state insurance mandates covering alcohol and other drug treatment. *J Ment Health Adm* 1992; 19(1):96-118.

Zweben JE, Payte JT. Methadone maintenance in the treatment of opioid dependence: a current perspective. *West J Med* 1990; 152(5):588-99.

Effective Medical Treatment of Opiate Addiction

A Continuing Medical Education Activity Sponsored by the National Institutes of Health/Foundation for Advanced Education in the Sciences

OBJECTIVE

The objective of this NIH Consensus Statement is to inform the biomedical research and clinical practice communities of the results of the NIH Consensus Development Conference on Effective Medical Treatment of Opiate Addiction. The statement provides state-of-the-art information regarding effective treatments for opiate addiction and presents the conclusions and recommendations of the consensus panel regarding these issues. In addition, the statement identifies those areas of study that deserve further investigation. Upon completing this educational activity, the reader should possess a clear working clinical knowledge of the state of the art regarding this topic.

ACCREDITATION

The National Institutes of Health/Foundation for Advanced Education in the Sciences is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The National Institutes of Health/Foundation for Advanced Education in the Sciences designates this continuing medical education activity for 1 credit hour in Category I of the Physician's Recognition Award of the American Medical Association. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

EXPIRATION

This form must be completed and postmarked by **November 19, 2000**, for eligibility to receive continuing medical education credit for this continuing medical education activity. The expiration date for this test may be extended beyond November 19, 2000. Beginning November 20, 2000, please check the NIH Consensus Development Program Web site (<http://consensus.nih.gov>) or call the NIH Office of Medical Applications of Research at 301-496-1144 for information regarding an extended expiration date for this continuing medical education activity.

INSTRUCTIONS

The consensus statement contains the correct answers to the following 12 questions. Select your answer(s) to each question and write the corresponding letter(s) in the answer space provided. Mail the completed test by the expiration date shown above to *CME Program, Office of Medical Applications of Research, National Institutes of Health, Building 31, Room 1B03, 31 Center Drive MSC 2082, Bethesda, MD 20892-2082*. You will receive notification of your test results within 2 to 3 weeks. If you have successfully completed the test (nine or more correct answers), you will receive a certificate for 1 hour of continuing education credit along with your test results. The estimated time to complete this educational activity is 1 hour. Photocopies of this form are acceptable. There is no fee for participating in this continuing education activity.



National Institutes of Health

Continuing Medical Education

1. **The evidence to support opiate addiction as a medical disorder includes:**

(You must indicate all that are true.)

- a. A consistency in the medical history, signs, and symptoms of opiate addiction irrespective of culture, ethnicity, and socioeconomic backgrounds.
- b. Pathophysiological changes in the brain.
- c. A strong tendency to relapse after long periods of abstinence.
- d. None of the above.

ANSWER: _____

2. **The consequences of an untreated opiate addiction include:**

(You must indicate all that are true.)

- a. Increased mortality rates.
- b. Decreased use of routine medical services.
- c. Increased prevalence of infectious diseases.
- d. Increased joblessness and criminal activity.
- e. None of the above.

ANSWER: _____

3. **Which of the following are true regarding opiate addiction:**

(You must indicate all that are true.)

- a. It is an increasing problem among young people.
- b. It is a major cause in the spread of HIV.
- c. A majority of opiate addicts are not in treatment.
- d. None of the above.

ANSWER: _____

4. **The current recommended duration of narcotic maintenance therapy is:**

- a. Less than 6 months.
- b. Between 1 and 2 years.
- c. Indefinitely.
- d. None of the above.

ANSWER: _____

5. **Which of the following narcotics are currently approved by FDA and available for opiate maintenance therapy? (You must indicate all that are true.)**

- a. Methadone
- b. Buprenorphine
- c. LAAM
- d. Clonidine

ANSWER: _____

6. **With regard to the use of methadone during pregnancy, which of the following is true? (You must indicate all that are true.)**

- a. HIV-infected women who receive methadone are more likely to be treated with zidovudine.
- b. The use of methadone during the third trimester should be avoided if possible.
- c. Babies whose mothers are treated with methadone during pregnancy have a greater likelihood of lower birth weight especially in contrast with babies whose mothers used heroin during pregnancy.
- d. Use of methadone during pregnancy, in conjunction with prenatal care, has been shown to decrease obstetrical and fetal complications.

ANSWER: _____

7. **Which of the following has been demonstrated to affect the outcome of narcotic maintenance treatment? (You must indicate all that are true.)**

- a. Adequate medication dosage.
- b. Psychosocial services.
- c. Duration and continuity of treatment.
- d. None of the above.

ANSWER: _____

8. Which of the following are true regarding medically supervised opioid withdrawal?

(You must indicate all that are true.)

- a. Various opioid and non-opioid medications had been demonstrated to be effective.
- b. The duration of the withdrawal process is directly proportional to the duration of subsequent sustained abstinence.
- c. Ultra-rapid anesthesia-aided withdrawal has been demonstrated in controlled studies to be a superior method for sustaining opioid abstinence.
- d. Relatively few opioid-addicted patients sustain abstinence after opioid withdrawal if other treatments are not initiated.

ANSWER: _____

9. Some of the common misconceptions concerning opiate addiction and opioid maintenance treatment include: *(You must indicate all that are true.)*

- a. Opiate addiction treatment is effective.
- b. Relapse after treatment is an indication of ineffective treatment.
- c. Opiate addiction is a medical illness.
- d. Opiate addiction is primarily limited to the mentally and socially impoverished.

ANSWER: _____

10. Important barriers to treatment include: *(You must indicate all that are true.)*

- a. Stigma.
- b. Inadequate treatment facilities.
- c. Federal, State, and local laws and regulations.
- d. Inadequate public and private funding.
- e. None of the above.

ANSWER: _____

11. Which of the following are true regarding molecular neurobiology and pathogenesis of opiate addiction? *(You must indicate all that are true.)*

- a. Twin, family, and adoption studies show that drug abuse vulnerability may be partially inherited.
- b. Cross-fostering adoption studies have identified several genetic pathways to drug abuse/dependence.
- c. Controlled family studies report significantly increased relative risk for substance abuse.
- d. None of the above.

ANSWER: _____

12. Which of the following are true with regard to the diagnosis of opiate addiction? *(You must indicate all that are true.)*

- a. Addiction is defined as a cluster of cognitive, behavioral, and physiological symptoms that are continued despite significant opiate-induced problems.
- b. The absence of opioids in saliva and urine is an important finding and indication that the individual is not addicted to opiates.
- c. Opiate dependence is characterized by repeated self-administration that often results in tolerance, withdrawal symptoms, and compulsive drug-taking.
- d. None of the above.

ANSWER: _____

Your response to the following four questions is optional and will have no effect on the grading results of this test.

To what extent did this CME activity meet the stated objectives?

- a. not at all
- b. very little
- c. somewhat
- d. considerably
- e. completely

ANSWER: _____

To what extent will participation in this CME activity enhance your professional effectiveness?

- a. not at all
- b. very little
- c. somewhat
- d. considerably
- e. completely
- f. does not apply

ANSWER: _____

Do you have additional comments you think would enhance the utility or impact of this NIH Consensus Statement?

Are there new topics you would like to have covered in a similar or related NIH Consensus Development Conference or Statement?

NAME *(Please type or print clearly)* _____

TITLE _____

ADDRESS _____

CITY _____ STATE _____ ZIP _____

PHONE _____ FAX _____

Please mail test to: CME Program
Office of Medical Applications of Research
National Institutes of Health
Building 31, Room 1B03
31 Center Drive MSC-2082
Bethesda, MD 20892-2082



U. S. DEPARTMENT OF HEALTH
AND HUMAN SERVICES
Public Health Service
National Institutes of Health
Office of Medical Applications of Research
Building 31, Room 1B03
31 Center Drive, MSC 2082
Bethesda, MD 20892-2082

Official Business
Penalty for private use \$300

BULK RATE
Postage & Fees
PAID
DHHS/NIH
Permit No. G802